Session Details
[Pj-018B]Japanese Poster Session 018B Neuroimmunology (NMO 1)
Wed. May 21, 2025 5:20 PM - 6:40 PM JST
Wed. May 21, 2025 8:20 AM - 9:40 AM UTC
Wed. May 21, 2025 8:20 AM - 9:40 AM UTC
ポスター会場(大阪国際会議場3F イベントホール)
Chair: Chihiro Fujii(Kansai Medical University Medical Center, Japan)
[Pj-018B-1]Our experience with ravulizumab for the treatment of neuromyelitis optica spectrum disorder
Etsuji Saji, Yuki Hatakeyama, Ayaka Ono, Kanako Sekiya, Hiroaki Nozaki, Masayoshi Tada, Shuichi Igarashi (Department of Neurology, Niigata City General Hospital, Japan)
[Pj-018B-2]Clinical characteristics of 5 cases of Neuromyelitis optica treated with Inebilizumab
Tetsuya Oyama, Yuuki Sakurai, Shouhei Nishimura, Kazuya Omichi, Yuuma Hayakawa, Junko Asada, Nobuyuki Iwade, Hirotaka Nakanishi (Yokkaichi City Hospital, Japan)
[Pj-018B-3]Report on changes in QOL in neuromyelitis optica patients treated with monoclonal antibody therapy
Akihiro Ueda1,2, Sayuri Shima2, Toshiki Maeda2, Msami Mizuno2, Reiko Odake2, Nozomi Sakai1, Yuzi Tsuzimura2, Konoka Kanda2, Syoko Ri2, Kunihisa Kato2, Ryunosuke Nagao2, Seiko Hirota2, Tomomasa Ishikawa1, Tetsuharu Kako1, Kazuya Kawabata2, Yasuaki Mizutani2, Mizuki Ito2,3, Shinji Ito1, Tatsuro Mutoh2, Hirohisa Watanabe2 (1.Fujita Health University Okazaki Medical Center Department of Neurology, Japan, 2.Fujita Health University School of Medicine Department of Neurology, Japan, 3.Fujita Health University Bantane Hospital, Japan)
[Pj-018B-4]Study of 4 cases of NMOSD treated with inebilizumab at our hospital
Mamoru Yamamoto, Syuhei Takasawa, Taichi Mitui, Hiroki Maesaka, Risako Furuta, Ryo Tanaka, Hiroaki Hirosawa, Noriyuki Matuda, Tomohiro Hayasi, Takamasa Nukui, Syunya Nakane, Yuji Nakatuji (University of Toyama, Department of Neurology, Japan)
[Pj-018B-5]Analysis of Cases Unable to Discontinue Steroids in NMOSD After Molecular Targeted Therapy
Kenzo Sakurai, Kei Kaburagi, Kenji Isahaya, Hisanao Akiyama, Yoshihisa Yamano (Department of Neurology, St. Marianna University School of Medicine, Japan)
[Pj-018B-6]Survey on Inebilizumab Use for NMOSD (5th interim analysis): Safety and Effectiveness
Kazuo Fujihara1,2, Shinya Hirota3, Hideki Aya3, Hideaki Hida3, Muneyoshi Kudo3, Satoshi Yuki3, Kyoko Kato3 (1.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University, Japan, 2.Multiple Sclerosis and Neuromyelitis Optica Center, Southern Tohoku Research Institute for Neuroscience, Japan, 3.Mitsubishi Tanabe Pharma Corporation, Japan)